We are live on
!
Find out more
JA
JLB & Associates Portfolio holdings
AUM
$696M
1-Year Est. Return
17.86%
This Fund
S&P 500
This Quarter
Est. Return
+1.76%
1 Year Est. Return
+17.86%
3 Year Est. Return
+57.72%
5 Year Est. Return
+93.63%
10 Year Est. Return
–
AUM
$275M
AUM Growth
+$7.11M
(+2.6%)
Cap. Flow
+$3.53M
Cap. Flow
% of AUM
1.28%
Top 10 Holdings %
Top 10 Hldgs %
30.46%
Holding
75
New
–
Increased
32
Reduced
36
Closed
1
Top Buys
| 1 |
Keurig Dr Pepper
KDP
|
+$1.54M |
| 2 |
Core Laboratories
CLB
|
+$1.33M |
| 3 |
Deluxe
DLX
|
+$1.32M |
| 4 |
SEI Investments
SEIC
|
+$758K |
| 5 |
Global Payments
GPN
|
+$645K |
Top Sells
| 1 |
Abbott
ABT
|
+$1.65M |
| 2 |
Cisco
CSCO
|
+$1.44M |
| 3 |
ALTR
Altera Corp
ALTR
|
+$658K |
| 4 |
Gilead Sciences
GILD
|
+$519K |
| 5 |
Occidental Petroleum
OXY
|
+$452K |
Sector Composition
| 1 | Technology | 18.87% |
| 2 | Healthcare | 16.29% |
| 3 | Consumer Discretionary | 15.68% |
| 4 | Industrials | 14.83% |
| 5 | Consumer Staples | 11.15% |
Similar funds
AAM
CA
CA
FCM
GUB
AWC
BBPWM
SCM
JLB & Associates's Q2 2014 Portfolio in Review
As of Q2 2014, JLB & Associates held 75 positions worth $275M, up 2.6% from $268M the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Trading was light in Q2 2014: portfolio turnover was 1.3%. JLB & Associates opened no new positions and exited 1, leaving the 75-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- JLB & Associates added most to Keurig Dr Pepper in Q2 2014, an estimated $1.54M increase.
- JLB & Associates's biggest Q2 2014 reduction was Abbott, cutting an estimated $1.65M.
- JLB & Associates fully exited QUESTCOR PHARMA INC in Q2 2014, selling an estimated $393K.
- JLB & Associates's ten largest holdings make up 30% of its $275M portfolio in Q2 2014.
- JLB & Associates opened 0 new positions and closed 1 in Q2 2014.
- JLB & Associates's portfolio value rose 2.6% quarter-over-quarter to $275M.
Based on JLB & Associates's 13F filing for Q2 2014, filed 11 Jul 2014.